Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Review of the first on-body injector (OBI) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma.
Journal: Expert opinion on drug delivery
Published: April 13, 2026
Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 08, 2025
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 03, 2025
Overcoming Barriers to Autologous Stem Cell Transplantation in Multiple Myeloma: Recommendations from a Multidisciplinary Roundtable Discussion.
Journal: Transplantation and cellular therapy
Published: April 21, 2023
Real-world multiple myeloma risk factors and outcomes by non-Hispanic Black/African American and non- Hispanic White race/ethnicity in the United States.
Journal: Haematologica
Published: January 25, 2023
Showing 1-5 of 5
Last Updated: 09/26/2026